Wu Tianyu, Xu Guixing, Hong Xiaojuan, Fan Huaying, Zeng Jiuzhi, Liu Yu, Hu Jinqun, Liang Fanrong, Yang Jie, Chen Jiao
School of Acupuncture-Moxibustion and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Affiliated Hospital of Chengdu University of Traditional Chinese Medicine (Sichuan Hospital of Traditional Chinese Medicine), Chengdu, Sichuan, China.
Front Endocrinol (Lausanne). 2024 Dec 19;15:1509152. doi: 10.3389/fendo.2024.1509152. eCollection 2024.
To explore whether acupuncture combined with clomiphene can reduce the luteinizing hormone-to follicle-stimulating hormone ratio and impact the gut microbiota in patients with obese polycystic ovary syndrome.
This open-label, randomized, parallel-group controlled trial included 86 women aged 20-40 years with obese polycystic ovary syndrome and 19 healthy controls. Participants were randomly assigned to either an acupuncture combined with clomiphene group or a clomiphene-only group, with a healthy control group for comparison. The treatment lasted three menstrual cycles, with acupuncture administered three times weekly and clomiphene given daily from day five of menstruation for five consecutive days per cycle. The primary outcome was the change in the luteinizing hormone-to-follicle-stimulating hormone (LH/FSH) ratio. Secondary outcomes included levels of other sex hormones, glucose and lipid metabolism parameters, self-rating anxiety and depression scale scores, and gut microbiota composition.
Intention-to-treat analysis showed that the adjusted mean luteinizing hormone-to follicle-stimulating hormone ratio decrease was -0.8 (95% CI: -1.14 to -0.46) in the acupuncture combined with clomiphene group and -0.22 (95% CI: -0.47 to 0.01) in the clomiphene group. The adjusted between-group difference was 0.53 (95% CI: 0.24 to 0.82, < 0.001). The levels of Agathobacter faecis increased, and those of , , and decreased after acupuncture combined with clomiphene treatment ( < 0.05).
Acupuncture combined with clomiphene may be safe and effective, reduce the luteinizing hormone-to follicle-stimulating hormone ratio, and improve insulin resistance in obese polycystic ovary syndrome, and these outcomes may be related to the gut microbiota.
探讨针刺联合克罗米芬是否能降低肥胖多囊卵巢综合征患者的黄体生成素与卵泡刺激素比值,并影响其肠道微生物群。
本开放标签、随机、平行组对照试验纳入了86名年龄在20至40岁之间的肥胖多囊卵巢综合征女性及19名健康对照者。参与者被随机分配至针刺联合克罗米芬组或单纯克罗米芬组,并设健康对照组进行比较。治疗持续三个月经周期,针刺每周进行三次,克罗米芬从月经第5天开始每日服用,每个周期连续服用5天。主要结局指标为黄体生成素与卵泡刺激素(LH/FSH)比值的变化。次要结局指标包括其他性激素水平、糖脂代谢参数、自评焦虑和抑郁量表评分以及肠道微生物群组成。
意向性分析显示,针刺联合克罗米芬组调整后的平均黄体生成素与卵泡刺激素比值下降了-0.8(95%CI:-1.14至-0.46),单纯克罗米芬组下降了-0.22(95%CI:-0.47至0.01)。调整后的组间差异为0.53(95%CI:0.24至0.82,<0.001)。针刺联合克罗米芬治疗后,粪栖杆菌属水平升高,而[此处原文缺失具体菌属名称]、[此处原文缺失具体菌属名称]和[此处原文缺失具体菌属名称]水平降低(<0.05)。
针刺联合克罗米芬可能安全有效,可降低肥胖多囊卵巢综合征患者的黄体生成素与卵泡刺激素比值,改善胰岛素抵抗,且这些结果可能与肠道微生物群有关。